Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
06:50pm, Tuesday, 07'th May 2024
Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.08 per share a year ago.
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
04:01pm, Tuesday, 07'th May 2024
First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA ® net product sales of $4.9 million Expanded Rigel's portfolio with ac
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:06am, Tuesday, 30'th Apr 2024
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
08:05am, Tuesday, 30'th Apr 2024
SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
07:00am, Monday, 29'th Apr 2024
Rigel Pharmaceuticals has multiple approved agents and a modest pipeline of developmental projects. The company has a stable financial position with growing sales and a new product in its stable. Rige
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Wednesday, 10'th Apr 2024
SOUTH SAN FRANCISCO, Calif. , April 10, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approv
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
08:05am, Thursday, 04'th Apr 2024
Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens Safety was consistent with the overall profile of olutasidenib
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
08:05am, Tuesday, 12'th Mar 2024
SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript
10:20pm, Tuesday, 05'th Mar 2024
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
06:11pm, Tuesday, 05'th Mar 2024
Rigel Pharmaceuticals (RIGL) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:01pm, Tuesday, 05'th Mar 2024
Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Expanded product portfolio with acqu
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
08:05am, Tuesday, 27'th Feb 2024
SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results afte
Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
08:30am, Friday, 23'rd Feb 2024
Rigel Pharmaceuticals reported promising preliminary Q4 and full-year 2023 results, with record-breaking net product sales for TAVALISSE and REZLIDHIA. The company's cash position remains healthy, pro
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
07:50am, Thursday, 22'nd Feb 2024
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisition of esta
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
09:36am, Monday, 19'th Feb 2024
Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.
